Pfizer sells midphase inflammatory drugs to mystery startup, exiting race against Bristol Myers
Pfizer is getting out of TYK2. Having studied its lead inhibitor in a raft of
Pfizer is getting out of TYK2. Having studied its lead inhibitor in a raft of
The world will be watching the US presidential election on Tuesday 3 November, but just